Background. The National Comprehensive Cancer Network guidelines recommend axillary imaging prior to neoadjuvant chemotherapy (NAC) in breast cancer patients who are clinically node negative (cN0) by physical examination. However, the benefit of this approach remains uncertain. The purpose of this study was to determine whether abnormal axillary imaging pre-NAC predicts nodal metastases post-NAC (ypN?) in cN0 patients. Methods. cN0 patients undergoing NAC followed by axillary surgery were identified. Rates of ypN? were compared among patients with abnormal pre-treatment axillary imaging vs. normal or no pre-treatment imaging using Fisher's exact test. Results. From May 2008 to March 2016, 402 eligible cN0 patients were identified. The median age of the patients was 49.5 years, and the median tumor size was 4 cm. Of these patients, 38% were estrogen receptor-positive (ER?) and human epidermal growth factor receptor 2-negative (HER2-), 30% were HER2? , and 32% were triple negative. All had pre-NAC mammograms, 40% axillary ultrasound, 83% MRI, and 51% PET. Abnormal nodes on imaging were seen in 208 patients (52%); 128 had pre-NAC node biopsy, and 75 were positive. Overall, 28% of the patients (n = 111) were ypN? post-NAC. Although the incidence of ypN? was significantly higher in patients with abnormal nodes on pre-NAC imaging (p = 0.001), 54% did not require axillary lymph node dissection (ALND) post-NAC. Among the patients with normal nodes on pre-NAC imaging, 20% were ypN? post-NAC. Conclusions. Half of patients with abnormal nodes on pre-NAC imaging did not require ALND post-NAC, while 20% of those with normal pre-NAC nodes had disease post-NAC, indicating that in cN0 patients already selected for NAC, axillary imaging pre-NAC does not predict the need for axillary surgery post-NAC with sufficient accuracy to be clinically useful.
Axillary ultrasound with selective needle biopsy of suspicious axillary nodes in patients with newly diagnosed breast cancer has been used for preoperative staging of the axilla for many years. 1 In clinically node negative (cN0) patients, Holwitt et al. 2 demonstrated that axillary ultrasound plus biopsy identified unsuspected nodal disease in 28% of the patients, obviating the need for sentinel node biopsy (SNB).
Following publication of the American College of Surgeons Oncology Group (ACOSOG) Z0011 trial, the routine practice of axillary ultrasound in cN0 patients undergoing primary surgery was called into question, 3 as Z0011 demonstrated that axillary lymph node dissection (ALND) could be safely omitted in cN0 patients undergoing breastconserving surgery with one or two positive sentinel nodes (SNs).
Comprehensive Cancer Network (NCCN) guidelines recommend consideration of axillary imaging with biopsy of any suspicious nodes prior to NAC in breast cancer patients found to be cN0 by physical examination alone. 5 One of the arguments supporting pre-NAC axillary imaging is improved selection for ALND post-NAC. However, one of the major benefits of NAC is axillary downstaging, with nodal pathologic complete response rates of 21-97%, depending on tumor subtype. 6, 7 Therefore, a decision to perform post-NAC ALND based on the finding of subclinical nodal metastases pre-NAC may result in unnecessary axillary surgery. The purpose of our study was to determine whether abnormal axillary imaging pre-NAC in cN0 patients was predictive of the presence of nodal metastases post-NAC.
METHODS
Following institutional review board approval, cN0 stage I-III breast cancer patients undergoing NAC between May 2008 and March 2016 were identified from a prospectively maintained database. Patients were staged as cN0 by physical examination. All the patients had a pretreatment mammogram. Axillary ultrasound, breast magnetic resonance imaging (MRI), and positron emission tomography (PET) were performed selectively at the discretion of the treating physicians. Information regarding the presence of abnormal axillary nodes by imaging and performance of pre-NAC lymph node biopsy was obtained by chart review.
Axillary lymph nodes were considered abnormal on mammogram when enlarged, dense, or observed to have loss of the fatty hilum. On ultrasound or MRI, nodes were considered abnormal if they had abnormal nodal morphology, including loss of fatty hilum and/or cortical thickening, eccentric cortical bulge, or cortical blood flow, regardless of nodal size. On PET, nodes were seen as abnormal if they had increased fluorodeoxyglucose (FDG) uptake and elevated standardized uptake value (SUV) without a defined SUV threshold. The choice for biopsy of abnormal nodes seen on pre-NAC imaging in cN0 patients was made by the treating physician.
Patient and tumor characteristics were recorded from the medical record. All patients had primary breast surgery and axillary surgery with either SNB or ALND. SNB was performed with isosulfan blue dye, technetium-99 m sulfur colloid, or a combination of both. ALND was performed for any positive SN. In patients with negative nodes, ALND also was performed for failed mapping, cT4 disease at presentation, or intraoperative suspicion of nodal disease.
Sentinel nodes were serially sectioned at 2 mm intervals along the major axis of the lymph node at the time of gross examination. A single hematoxylin and eosin (H&E)-stained section was prepared from each block. Immunohistochemistry was not routinely performed for lymph node evaluation post-NAC.
Clinical variables were summarized using frequency and percentage for categorical covariates, and median and range for continuous covariates, and compared by imaging and pre-NAC biopsy result using Fisher's exact test for categorical variables and the Wilcoxon rank-sum test for continuous variables. Rates of nodal metastases post-NAC (ypN?) and ALND were compared between patients with abnormal pretreatment axillary imaging and patients with normal or no pretreatment imaging using Fisher's exact test and the Wilcoxon rank-sum test. A multivariable logistic regression model was fit to assess the effect of abnormal axillary imaging on rates of ypN? and ALND post-NAC after adjusting for clinical tumor size, histology, and receptor status. All statistical analyses were performed with R 3.1.1 (R Foundation, Vienna, Austria), and p values \0.05 were considered significant.
RESULTS
Between May 2008 and March 2016, 402 cN0 patients received NAC followed by axillary surgery. Table 1 describes the clinical characteristics of the study cohort. The median age of the patients was 49.5 years, and the median clinical tumor size was 4 cm. Of these patients, 30% had human epidermal growth factor receptor 2 (HER2) positive tumors, and 32% had triple-negative tumors.
All patients had a pre-NAC mammogram. Axillary ultrasound was performed in 162 patients (40%), breast MRI in 332 patients (83%), and PET scan in 205 patients (51%). Abnormal nodes were seen in 208 patients (52%) by any imaging method. Specifically, abnormal nodes were seen on 12% of mammograms (n = 46), 81% of ultrasounds (n = 131), 46% of MRIs (n = 154), and 51% of PET scans (n = 104).
The clinicopathologic characteristics of the patients with and without abnormal nodes by imaging are described in Table 2 . Patients with abnormal nodes on imaging had larger tumors (4 vs. 3.5 cm; p = 0.002) and were more likely to have ductal histology (92 vs. 86%; p = 0.048); otherwise, the groups did not differ. When the patients who had abnormal nodes imaged by axillary ultrasound (n = 131) were compared with those who had a normal axillary ultrasound (n = 31) or no axillary ultrasound (n = 240), the clinicopathologic characteristics did not significantly differ between the groups (Table 3) .
Lymph node biopsy prior to NAC was performed in 128 patients; 75 were positive for tumor cells, 51 were negative, and 2 were non-diagnostic. The remaining patients did not have a node biopsy. When the patients with and without a positive pre-NAC lymph node biopsy were compared, age, clinical tumor size, receptor status, histology, and clinical T stage did not differ (p = NS).
SNB alone was performed in 254 patients, 77 had an SNB followed by ALND, and 71 had ALND alone. In the 331 patients who had an SNB attempted, dual tracer mapping was used in 93%, and 330 (99.7%) were successfully mapped; the median number of SNs removed was 4 (range, [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] . In the 148 patients treated with ALND, the median number of nodes removed was 17 (range, 1-46).
Among patients who had an SNB procedure (n = 330), there was no difference in the median number of SNs removed between patients with and without abnormal nodes on imaging (4 vs. 4, respectively; p = 1.0) or with and without a positive pre-NAC LN biopsy (3 vs. 4, respectively; p = 0.83).
After the completion of NAC, 111 patients (28%) had nodal metastases (ypN?), with a median of two positive nodes (range, 1-16). Breast pathologic complete response, defined as the absence of invasive disease in the breast (in situ allowed), was observed in 35% of the 402 patients. The incidence of histologically positive nodes post-treatment was higher among the patients with abnormal nodes than among those with normal nodes, as shown by axillary ultrasound (40 vs. 23%; p = 0.1), MRI (34 vs. 17%; p \ 0.001), and PET (42 vs. 21%; p \ 0.001), although the difference did not reach statistical significance in the axillary ultrasound group (Table 4 ). The patients with and without abnormal nodes on imaging had a similar median number of positive nodes post-NAC: 2.5 vs. 2, respectively (p = 0.83). Among patients with abnormal nodes seen by any imaging modality (n = 208), 65% had histologically negative nodes post-NAC and 54% did not receive an ALND. For patients with normal nodes on imaging pre-NAC, 20% were ypN? post-NAC and 27% had an ALND (Table 4) 
DISCUSSION
It is well established that clinically node-negative breast cancer patients may harbor microscopic disease in the axillary lymph nodes, with a frequency of nodal metastases ranging from 10 to 88% depending on tumor type, tumor ER estrogen receptor; HER2 human epidermal growth factor receptor 2 a Metaplastic (n = 2), neuroendocrine (n = 2) NAC neoadjuvant chemotherapy; ER estrogen receptor; HER2 human epidermal growth factor receptor 2 size, multifocality, receptor status, and patient age. 8 However, in cN0 patients selected for NAC based on other tumor characteristics, the role of pretreatment axillary imaging to identify occult disease in the axilla that may be downstaged with chemotherapy remains uncertain. Randomized trials and institutional experiences have shown that the incidence of nodal positivity is lower in patients treated with NAC compared to those undergoing initial surgery. Among 1493 patients with T1-T3 N0-1 operable breast cancer enrolled in National Surgical Adjuvant Breast and Bowel Project (NSABP) B-18, the incidence of pathologically negative nodes was 58% for the patients randomized to preoperative therapy compared with 42% for those receiving postoperative therapy (p \ 0.0001). 9 Similarly, Hunt et al. 10 demonstrated a lower incidence of SN positivity among patients receiving NAC (n = 575) compared to those having surgery first (n = 3171), which resulted in significantly fewer ALNDs performed in patients presenting with T2 disease (27.2 vs. 40.6%; p \ 0.0001) or T3 disease (45.1 vs. 65.7%; p = 0.045).
This study also demonstrated no increase in regional recurrence rates in patients undergoing axillary staging post-NAC, confirming the safety of this approach. In patients receiving NAC, it is the post-treatment status of the nodes, not the pretreatment status, that determines surgical management. For cN0 patients already selected to undergo NAC, axillary imaging with identification of suspicious nodes is useful only if the imaging study consistently identifies the patients more likely to have nodal metastases post-NAC.
In our study, 111 cN0 patients (28%) had histologically positive nodes post-NAC. Although the patients with abnormal nodes on pretreatment imaging had a higher incidence of nodal positivity post-NAC (35 vs. 20%; p = 0.001), ALND was avoided for the majority of the patients, irrespective of pretreatment imaging findings (ALND rate: 46% abnormal nodes vs. 27% normal nodes). Importantly, the patients with normal nodes shown on pretreatment imaging still had a substantial incidence of nodal positivity post-NAC (20%), suggesting that pretreatment axillary imaging does not reliably predict the need for ALND following systemic therapy. These findings are consistent with the known false-negative rate of preoperative axillary evaluation by axillary ultrasound, MRI, and PET, with documented false-negative rates of 25%, 11 35%, 12 and 79%, 13 respectively, and explain why approximately 20% of the patients in our study with normal nodes on imaging pre-NAC were histologically node positive post-NAC.
Another possible explanation for the poor correlation between pretreatment axillary imaging and nodal positivity post-NAC is that the status of the axilla post-NAC in cN0 patients is influenced by both the initial nodal status and the response of the tumor to chemotherapy. In our study, although abnormal axillary imaging was a predictor of nodal positivity post-NAC (OR, 2.95; p \ 0.001), additional predictors of residual positive nodes post-NAC were (8) 26 (11) ER estrogen receptor; HER2 human epidermal growth factor receptor 2 a p Value for ultrasound performed versus not performed nonductal histology (OR, 2.93; p = 0.003) and estrogen receptor positivity (OR, 3.94; p \ 0.001), with hormone receptor status being the strongest predictor of nodal disease. The finding that patients with ductal histology were more likely to have abnormal nodes on pre-NAC imaging (p = 0.048) and yet less likely to harbor positive nodes post-NAC supports existing data showing that lobular cancers are less responsive to NAC, with a higher disease burden post-treatment than ductal cancers, largely due to their strong estrogen receptor positivity. 14, 15 Overall, patients with ER? tumors not only have a higher rate of nodal metastases at presentation than those with ER-tumors; 8, 16 they also have a significantly lower rate of nodal pCR than patients with triple-negative or HER2? breast cancers. 6, 7 Although not directly evaluated in our study, the higher likelihood of nodal metastases in ER? patients post-NAC suggests that in the clinically node-negative subset of patients who meet Z0011 eligibility criteria at presentation, consideration of initial surgery as a more likely approach to avoiding ALND is appropriate. In aggregate, the findings in our study support the concept that tumor subtype, not pretreatment imaging findings, is the most important predictor of nodal metastases and ALND post-NAC.
One argument in favor of pre-NAC axillary imaging is that identification of positive axillary nodes in cN0 patients pre-NAC may influence recommendations for radiation post-NAC, particularly in patients undergoing mastectomy. In women with positive nodes treated with initial surgery, postmastectomy radiation therapy reduces locoregional recurrence and improves overall survival, particularly in women with 4 or more positive nodes. 17 However, initial nodal status is less important in patients receiving NAC, as the post-treatment status of the axilla is the primary determinant of locoregional recurrence.
In a review of NSABP B-18 and NSABP B-27, studies that did not allow the use of postmastectomy radiotherapy, Mamounas et al. 18 demonstrated a low incidence of locoregional recurrence \10% among patients who achieved a nodal pathologic complete response with NAC, regardless of clinical nodal status at presentation, suggesting that identification of nodal disease with axillary imaging in cN0 patients pre-NAC should not substantially alter treatment decisions.
This study was limited by the retrospective nature of the axillary imaging review. A re-review of the imaging may have identified additional patients with suspicious axillary imaging, which could have influenced the association with pathologic nodal status post-NAC. However, in clinical practice, imaging is traditionally read by a single radiologist without re-review, so the reported data reflect the association more likely to be observed in everyday practice. Furthermore, although we found no difference in the clinical characteristics between the patients with and without abnormal nodes, it is possible that the finding of abnormal axillary imaging influenced the decision for preoperative chemotherapy, particularly in patients with T1 disease, suggesting a small clinical benefit to preoperative imaging in selected patients.
In conclusion, in a cohort of cN0 patients receiving NAC, half of the patients with abnormal nodes on pre-NAC imaging did not require ALND post-NAC, whereas 20% of those with normal pre-NAC nodes had disease post-NAC, indicating that in cN0 patients already selected to receive preoperative chemotherapy, axillary imaging pre-NAC does not predict the need for axillary surgery post-NAC with sufficient accuracy to be clinically useful.
